Aetna expands bundled prior authorization for Medicaid cancer care
Aetna, a CVS Health company, expanded a bundled prior authorization program across all cancer types for eligible Medicaid members effective September 1, 2026, combining medical oncology, radiation oncology and related high-tech imaging in a single submission through the Eviti portal. The company said providers were filing an average of four separate prior authorizations per cancer patient and that nearly 25% of eligible members received bundled authorizations during the initial rollout. Aetna plans to extend the program to Medicare and commercial members in the first half of 2027 and to all lines of business that year.
Aetna bundles multiple oncology authorizations into one Eviti portal submission.
Context
Aetna piloted bundled oncology authorizations and saw early adoption near 25%. The company expanded the program for eligible Medicaid members on September 1, 2026. Aetna plans wider rollout to Medicare and commercial members in 2027.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked